Geode Capital Management buys $1,274.6 Million stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Geode Capital Management scooped up 353,474 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 23,656,034 shares of Merck & Co. which is valued at $1,274.6 Million.Merck & Co. makes up approximately 0.71% of Geode Capital Management’s portfolio.

Other Hedge Funds, Including , Bridgewater Associates Lp boosted its stake in MRK in the latest quarter, The investment management firm added 54,500 additional shares and now holds a total of 210,746 shares of Merck & Co. which is valued at $11.4 Million. Merck & Co. makes up approx 0.15% of Bridgewater Associates Lp’s portfolio.Wills Financial Group reduced its stake in MRK by selling 69 shares or 0.28% in the most recent quarter. The Hedge Fund company now holds 24,226 shares of MRK which is valued at $1.3 Million. Merck & Co. makes up approx 1.13% of Wills Financial Group’s portfolio.Vsr Financial Services boosted its stake in MRK in the latest quarter, The investment management firm added 9,008 additional shares and now holds a total of 64,444 shares of Merck & Co. which is valued at $3.5 Million. Merck & Co. makes up approx 0.36% of Vsr Financial Services’s portfolio.Wellington Shields Capital Management boosted its stake in MRK in the latest quarter, The investment management firm added 1,611 additional shares and now holds a total of 49,369 shares of Merck & Co. which is valued at $2.6 Million. Merck & Co. makes up approx 0.45% of Wellington Shields Capital Management’s portfolio.Dowling Yahnke boosted its stake in MRK in the latest quarter, The investment management firm added 1,918 additional shares and now holds a total of 107,577 shares of Merck & Co. which is valued at $5.9 Million. Merck & Co. makes up approx 0.72% of Dowling Yahnke’s portfolio.

Merck & Co. opened for trading at $55.81 and hit $56.67 on the upside on Wednesday, eventually ending the session at $56.57, with a gain of 1.74% or 0.97 points. The heightened volatility saw the trading volume jump to 96,01,393 shares. Company has a market cap of $156,587 M.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.